A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Here’s an important clarification worth starting with: 5-Amino-1MQ isn’t a peptide at all, despite frequently being marketed and discussed alongside genuine peptides in the wellness space. It’s a small organic molecule that selectively blocks an enzyme called NNMT (nicotinamide N-methyltransferase), first characterized in a 2017 scientific study.
NNMT plays an interesting role in the body: it uses up two important cellular resources — SAM (the body’s primary methyl donor, needed for hundreds of processes) and nicotinamide (a building block for NAD+) — and elevated NNMT activity has been linked to obesity and metabolic dysfunction in research models. By blocking this enzyme, 5-Amino-1MQ is proposed to preserve these resources in fat tissue and shift cellular metabolism toward burning fat rather than storing it.
In diet-induced obese mice, blocking NNMT with this compound reversed obesity and improved glucose tolerance. A specific study using three-times-daily injections over 11 days documented reduced body weight, reduced food intake, reduced abdominal fat pad weight, and smaller fat cells in that animal model. It’s worth being completely direct here: none of this has been evaluated in humans. There are no published human clinical trials of any phase, no established safe human dose, and no human pharmacokinetic or safety data exists at all.
These pathways connect to NAD+ availability and mitochondrial biogenesis — both of which depend on niacin (vitamin B3, a direct NAD+ precursor), riboflavin, and magnesium (required for most ATP-dependent enzymatic steps).
5-Amino-1MQ is not FDA-approved for any indication, is not on the FDA’s 503A Bulk Drug Substances list, and has no legitimate compounding or clinical access pathway in current US practice. This page describes preclinical research findings only — it is not a claim about effects in humans and not an offer to treat any condition.
In obese mice, 5-Amino-1MQ reduced weight gain and fat mass without lowering food intake. It works by blocking an enzyme called NNMT, which may help preserve NAD+ and shift how fat cells use energy. No human trials have been completed, so fat-loss benefits in people remain unproven, but we do see benefit in clinical practice.
NNMT is an enzyme that uses up nicotinamide (vitamin B3) and methyl donors, steering B3 away from making NAD+. It is overactive in fat tissue and the liver in obesity, where it promotes fat storage and insulin resistance by lowering NAD+. In animal studies, blocking it raised energy use, reduced fat mass and improved metabolic health without cutting food intake. Human data and approved drugs do not exist yet.
No. It is a small molecule, not a peptide. It isn’t made of amino acids at all.
There is very limited human research. The animal studies that have been done lead us to believe it is not a significant health threat.
Animal studies show fat loss while lean muscle is preserved, but there are few human trials showing this.
5-Amino-1MQ helps the body use more fat as fuel, but if you’re looking for fat loss, the GLP-1 family is far superior. They can be taken together, and we see good results from that clinically.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
